Replies to post #359823 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Yeah spend, spend, spend why lying about timing of potentially revenue driving catalysts.

Absolutely fabulous!

[kund]

As I use to say municipality sewer pipe is better than Misleading's pipeline. He just lies and lies

[rayovacAAA]

PURE B.S.!!!!!!!!

This is quite an impressive list of plans for a small company working in a complex environment.

[georgejjl]

Nidan, I agree 100%

This is quite an impressive list of plans for a small company working in a complex environment.
IMO:

Pipeline expansion of the ANAVEX platform using gene biomarkers of response, applying precision medicine for neurological disorders with unmet medical need are expected 2022:

Meeting with FDA for discussing ANAVEX®2-73 Parkinson’s disease program including pivotal Phase 3 study.
Planned initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical study.
Planned initiation of a potentially pivotal Phase 2/3 study in Fragile X Syndrome, the most frequent genetic cause of autism spectrum disorder.
Planned initiation of a Phase 2/3 clinical trial for the treatment of a new rare-disease indication.
Planned initiation of ANAVEX®3-71 Phase 2 clinical trials for FTD, schizophrenias and Alzheimer’s disease indications.

https://ih.advfn.com/stock-market/NASDAQ/anavex-life-sciences-AVXL/stock-news/88059881/anavex-life-sciences-provides-business-update-and

Good luck and GOD bless,

[Bourbon_on_my_cornflakes]

HUGELY Disappointing:

Meeting with FDA for discussing ANAVEX®2-73 Parkinson’s disease program including pivotal Phase 3 study. WhyTF hasn't this occurred already They have had the results for what, 2 year now?

Planned initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical study. WhyTF hasn't this occurred already

Planned initiation of a potentially pivotal Phase 2/3 study in Fragile X Syndrome, the most frequent genetic cause of autism spectrum disorder. WhyTF hasn't this occurred already They have had more than two years to prepare this.

Planned initiation of a Phase 2/3 clinical trial for the treatment of a new rare-disease indication. WhyTF hasn't this occurred already Enough of the tease. They have had more than two years to prepare this.

Planned initiation of ANAVEX®3-71 Phase 2 clinical trials for FTD, schizophrenias and Alzheimer’s disease indications. OK, get it started.